Moonwalk Biosciences, an epigenetic biology and AI company, announced the appointment of John Liles, Ph.D., as VP Biology and Translational Science, and the formation of a world class Cardiometabolic Advisory Board. Dr. Liles brings deep experience as a drug discovery biologist with proven success advancing novel therapeutics from target discovery through IND for liver, kidney, lung and cardiovascular diseases.
In addition, a leading advisory board of scientific and clinical experts in adipocyte and liver biology bring invaluable insights to Moonwalk’s research programs and therapeutic development efforts to address unmet needs in cardiometabolic disease.
“We are thrilled to welcome John to our team and announce the formation of our cardiometabolic advisory board,” said Alex Aravanis, M.D., Ph.D., Co-founder & CEO, Moonwalk Biosciences, “John’s expertise in translating innovative therapeutics from discovery through IND will accelerate our ambitious R&D efforts.”
Also Read: Momentum & Cube Biotech Announce Strategic Partnership
Dr. Liles brings more than 17 years of experience to Moonwalk, most recently as Executive Director, Kidney Disease Research & Strategy at Chinook Therapeutics (acquired by Novartis), where he was the head of the research group responsible for target discovery and pipeline expansion. At Gilead Sciences, he led Research and Pharmacology teams for more than 15 years, achieving five INDs and contributing to the advancement of approved cardiovascular drugs. He earned his Ph.D. in Pharmacology from Tulane University, and completed his post-doc at the National Academy of Sciences.
“I’m excited to join the Moonwalk team at a pivotal time as the company advances its preclinical efforts to pioneer new insights about epigenetic biology and engineering cell state,” said Dr. Liles. “Having operated in cardiometabolic diseases, I appreciate the role of epigenetics in the regulation of adipose and liver tissue biology. We’ve seen the significant impact of current cardiometabolic therapies, and I believe the future holds even greater potential to yield novel mechanisms of action and improved therapeutic profiles. Better elucidating this biology is a rich area for new discoveries, and could represent a large therapeutic opportunity.”
SOURCE: Businesswire